KLK3 and pachyonychia congenita: This retrospective analysis of high-dose PBT and ADT for Japanese PC patients showed that short-term adjuvant ADT is necessary for intermediate-risk PC patients with multiple risk factors (i.e., T2b–T2c, PSA level 10–20 ng/mL, or GS 7), but it may be unnecessary for those with a single risk factor.